Can Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate cost

Simple item page
dc.contributor.authorRoberts, Thomas Geralden_ZA
dc.date.accessioned2014-08-02T07:32:06Z
dc.date.available2014-08-02T07:32:06Z
dc.date.issued2003en_ZA
dc.descriptionIncludes bibliographical references.
dc.description.abstractRecently, effective oral cancer drugs are gaining prominence. This trend toward oral chemotherapy has important economic implications: the Medicare system of the United States pays for all intravenous (IV) chemotherapy, but it covers only those oral drugs that have an equivalent IV formulation approved by the Food and Drug Administration (FDA). The majority of oral cancer drugs in the cancer pipeline do not have such an IV equivalent. There are two proposals before the United States Congress to expand the Medicare program to cover all oral cancer drugs. Gefitinib (Iressa; AstraZeneca) is one of the most interesting of the cohort of novel, targeted oral cancer drugs. Already approved in Japan, it is currently under review by the U.S. FDA. This drug has relatively modest efficacy and few side effects; but it is likely to be expensive. Because the sponsor is seeking approval for the treatment of lung cancer, with a large annual incidence, the economic implications of an FDA approval for gefitinib have raised considerable concern.en_ZA
dc.identifier.apacitationRoberts, T. G. (2003). <i>Can Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate cost</i>. (Thesis). University of Cape Town ,Faculty of Humanities ,Department of Sociology. Retrieved from http://hdl.handle.net/11427/5959en_ZA
dc.identifier.chicagocitationRoberts, Thomas Gerald. <i>"Can Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate cost."</i> Thesis., University of Cape Town ,Faculty of Humanities ,Department of Sociology, 2003. http://hdl.handle.net/11427/5959en_ZA
dc.identifier.citationRoberts, T. 2003. Can Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate cost. University of Cape Town.en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Roberts, Thomas Gerald AB - Recently, effective oral cancer drugs are gaining prominence. This trend toward oral chemotherapy has important economic implications: the Medicare system of the United States pays for all intravenous (IV) chemotherapy, but it covers only those oral drugs that have an equivalent IV formulation approved by the Food and Drug Administration (FDA). The majority of oral cancer drugs in the cancer pipeline do not have such an IV equivalent. There are two proposals before the United States Congress to expand the Medicare program to cover all oral cancer drugs. Gefitinib (Iressa; AstraZeneca) is one of the most interesting of the cohort of novel, targeted oral cancer drugs. Already approved in Japan, it is currently under review by the U.S. FDA. This drug has relatively modest efficacy and few side effects; but it is likely to be expensive. Because the sponsor is seeking approval for the treatment of lung cancer, with a large annual incidence, the economic implications of an FDA approval for gefitinib have raised considerable concern. DA - 2003 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2003 T1 - Can Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate cost TI - Can Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate cost UR - http://hdl.handle.net/11427/5959 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/5959
dc.identifier.vancouvercitationRoberts TG. Can Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate cost. [Thesis]. University of Cape Town ,Faculty of Humanities ,Department of Sociology, 2003 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/5959en_ZA
dc.language.isoengen_ZA
dc.publisher.departmentDepartment of Sociologyen_ZA
dc.publisher.facultyFaculty of Humanitiesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.subject.otherSociologyen_ZA
dc.titleCan Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate costen_ZA
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationnameMSocScen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_hum_2003_roberts_tg (1).pdf
Size:
4.29 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Masters